Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.635 USD | -2.84% | -4.69% | +0.71% |
05-09 | Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating | MT |
05-08 | C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.71% | 399M | |
+65.24% | 62.59B | |
-1.34% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.30% | 26.21B | |
-21.75% | 19.09B | |
+4.98% | 13.08B | |
+25.59% | 12.26B | |
+28.44% | 12.05B |
- Stock Market
- Equities
- CCCC Stock
- News C4 Therapeutics, Inc.
- Credit Suisse Initiates C4 Therapeutics at Underperform with $10 Price Target, Says Risk Related to Lead Program Too High